Pharmaceutical Executive May 26, 2023
Ahead of ASCO and BIO, Michael Bailey CEO of AVEO Oncology, discusses the company becoming a LG Chem subsidiary and the future for drug development in the combined entity.
In late February, Michael Bailey, CEO of AVEO Oncology, was preparing to head from Boston to Fort Myers, Florida for an all-company meeting. A meeting that would be vastly different from previous AVEO Oncology all-company meetings because it was the first time as a wholly-owned subsidiary of Seoul, South Korea-based LG Chem.
The acquisition was announced October 2022 and closed January 19, 2023. Bailey said, “We spent the last six months working together to understand each other’s processes and systems so that as we moved forward it didn’t disrupt the daily...
Today's Sponsors
Today's Sponsor